Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem-cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular mechanisms underlying the development of this myeloproliferative syndrome are currently unknown. In order to identify tumor suppressor genes that may be involved in the disease process, we performed an analysis for loss of heterozygosity (LOH) in CD34 þ cells from 29 patients with MMM. We observed a frequency of allelic loss on chromosomal arm 3p in 24% of cases. Detailed mapping of 3p revealed a distinct region of deletion at 3p24. Among the genes known to map within this region is the retinoic acid receptor-b (RARb2) gene. To determine whether RARb2 gene activity is diminished in this disease, we analysed its expression in CD34 þ cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARb2 is significantly decreased in 100% of patient samples compared to that in CD34 þ cells from 10 normal individuals. Since allelic loss at 3p24 occurs in o25% of patients, we investigated the contribution of epigenetic modifications to RARb2 inactivity. Using methylationspecific PCR, we found hypermethylation of RARb2 in 16 of 18 patients (89%), while the methylated form of the gene was absent in CD34 þ cells from nine normal individuals. Our results suggest that RARb2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RARb2 gene activity in these patients.
Introduction
Myelofibrosis with myeloid metaplasia (MMM) is classified as a chronic myeloproliferative disease. The primary pathogenetic mechanism is a clonal stem-cell disorder that leads to ineffective erythropoiesis, dysplastic megakaryocytic hyperplasia, and an increase in the ratio of immature myeloid cells to total granulocytes. This clonal myeloproliferation is characteristically accompanied by bone marrow fibrosis and by extramedullary hematopoiesis in the spleen and other organs (Tefferi, 2000) . Although aberrant expression of fibrogenic and angiogenic cytokines has been demonstrated in patients with MMM (Martyre et al., 1994; Mesa et al., 2000) , the molecular events that lead to the disease process have not been characterized.
Like other cancers, malignant transformation of hematopoietic cells results from a series of genetic changes. The inactivation of tumor suppressor genes is a crucial event in oncogenesis and may occur by a variety of mechanisms. Loss of heterozygosity (LOH) in tumor cells has proven useful in mapping regions of chromosomes that contain putative altered tumor suppressor genes (Thiagalingam et al., 2002) . The paradigm for LOH studies is that one allele of a tumor suppressor gene is mutated and the remaining normal allele is lost leading to homozygous inactivation of the gene. Although chromosomal alterations in MMM have been studied (Tefferi et al., 2001) , routine cytogenetic analyses are only able to detect relatively large deletions. LOH analysis, however, allows for more precise delineation of critically deleted regions. In addition to these genetic mechanisms used by tumors to escape growth controls, malignant cells use epigenetic mechanisms to silence genes that impede rapid cell growth (Jones and Baylin, 2002) . For example, tumor suppressor genes can be silenced by reversible modification of regulatory promoters with methyl groups, either on both alleles or on just one when the other has been deleted.
In this study, we present a complete allelotype analysis of 29 cases of MMM. We identify several regions with a high frequency of LOH and map one of these regions (the short arm of chromosome 3) in detail. We uncover the potential involvement of the tumor suppressor gene, RARb, in the development of MMM and present multiple mechanisms for its loss of expression in this disease.
Results
To identify tumor suppressor genes that may be involved in the disease process, we performed a genome-wide screening for LOH in 29 patients with MMM. For this analysis, we compared allelic loss in CD34 þ cells from patients with MMM to that of normal T lymphocytes from the same patients. Using a total of 86 polymorphic microsatellite markers (listed in Table 1 ), we analysed each sample at two or more loci per autosomal arm. Markers on the same arm were combined, and the frequency of LOH for each arm is shown in Figure 1 . Specific loci with incidence of LOH are given in Table 2 .
The most frequent allelic loss was observed on 1q (25%), 3p (24%) and 3q (22%). A frequency of LOH of 15-20% of the informative cases was also observed on chromosomal arms 1p, 8p, and 12q. These findings are compared with the results of cytogenetic analysis in Table 3 . Of 13 patients (nos. 1, 6, 10, 12, 13, 14, 15, 17, 18, 19, 20, 24, and 25) for whom normal karyotypes were found by standard cytogenetic analyses, we identified deletions in five of them (nos. 6, 13, 14, 19, and 20) . In fact, patient number 19 had LOH at one or more loci on nine chromosomal arms, thus emphasizing that LOH analysis can reveal allelic losses not previously identified by more routine methods. A representative autoradiogram of LOH found on chromosomal arm 3p is shown in Figure 2 .
Deletions on the short arm of chromosome 3 are among the most common alterations in many types of cancer, thus suggesting the presence of one or more tumor suppressor genes in this location. Based on this and the evidence that 3p showed one of the highest frequencies of LOH in 29 MMM samples, we next Figure 1 Frequency of allelic loss on individual chromosomal arms in MMM. Allelotyping was performed using the polymorphic microsatellite markers listed in Table 1 . The data for markers on the same arm were combined to show any allelic loss on that arm. Frequency of LOH for each arm was calculated as the total number of cases with LOH divided by the total number of informative cases. The most frequent allelic loss was observed on chromosome arms 1q (25%), 3p (24%), 3q (22%), 8p (18%), and 12q (16%) RARb2 and myelofibrosis with myeloid metaplasia LC Jones et al performed a detailed deletional map of the region between D3S1597 and D3S1578 using 23 additional microsatellite markers. The pattern of LOH for each positive patient is shown in Figure 3 . Six samples showed LOH at one or more loci on chromosomal arm 3p; four of these had a commonly deleted region between D3S1583 and D3S1609 at 3p24 (estimated size is approximately 4 Â 10 6 bp). We hypothesize that loss of a tumor suppressor gene within this region plays a role in the progression of MMM.
We analysed the chromosomal map of this region and found that the retinoic acid receptor b (RARb2) gene is located at 3p24. RARb2 is considered to be a putative tumor suppressor in several other types of cancer (Widschwendter et al., 1997; Xu et al., 1997a, b; Qiu et al., 1999; Toulouse et al., 2000a; Di Croce et al., 2002) . To determine if inactivation of RARb2 plays a potential role in the development of myelofibrosis, we analysed its expression in CD34 þ cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARb2 is greatly diminished in 100% of patient samples compared to expression in CD34 þ cells from 10 normal individuals (Figure 4) . Loss of expression of RARb2 in all MMM samples implicates this gene in the disease process.
The expression of RARb2 in human myeloid progenitors has not been previously characterized. Therefore, we examined RARb2 expression during Figure 2 Representative autoradiograph showing LOH at 3p24 using microsatellite marker D3S1266. LOH is detected in sample no. 8 (allelic loss is indicated by an arrow), whereas both alleles are present in sample no. 6. N, DNA from normal CD3 þ cells; T, DNA from CD34 þ cells hematopoietic differentiation along the myeloid pathway. For these studies, normal CD34 þ cells were cultured in the presence of IL-3 and GM-CSF for 12 days (Morosetti et al., 1997) , and differentiation was confirmed by cell morphology. While expression of RARb2 was high in CD34 þ cells, its expression markedly decreased as cells matured toward granulocytes ( Figure 5 ). By day two, RARb2 expression decreased by 75% and remained low throughout myeloid differentiation. As expected, expression of CD34 mRNA decreased by day five with a concomitant increase in CD11b expression ( Figure 5 , inset). These results suggest an important role for RARb2 at the progenitor stage. Our LOH analysis revealed deletions at 3p24 in only 21% of cases, thus suggesting that a mechanism other than allelic loss inactivates RARb2 activity in MMM.
Aberrant methylation of CpG islands has been identified as an epigenetic mechanism for the transcriptional silencing of tumor suppressor genes. To analyse the methylation status of the RARb gene promoter P2 in patients with myelofibrosis, we performed methylationspecific PCR (MSP) on bisulfite-modified DNA samples by simultaneous use of primers for the methylated and unmethylated forms of the promoter. For MSP, genomic DNA was isolated from CD34 þ cells from 18 patients with MMM and compared to the methylation status of DNA from normal CD34 þ cells. We found hypermethylation of RARb2 in 16 of 18 (89%) patients, while the methylated form of the gene was absent in CD34 þ cells from nine normal individuals ( Figure 6 ). These results, in combination with our findings in Figure 4 , suggest that RARb2 acts as a 
Discussion
MMM is classified with polycythemia vera (PV), essential thrombocythemia (ET), and chronic myeloid leukemia (CML) as a myeloproliferative disease. Unlike the Philadelphia chromosome in CML (Rowley, 1973; Bartram et al., 1983) , no hallmark chromosomal aberration has been demonstrated in PV, ET, or MMM. Chromosomal abnormalities are seen in 15 and 30% of patients with PV and MMM, respectively, but are rare in ET (reviewed in Bench et al., 2001) . Hence, the pathogenetic mechanism that leads to abnormal proliferation of hematopoietic cells in these syndromes is yet to be defined. Previous cytogenetic analyses (Tefferi et al., 2001) of patients with MMM indicate that the most frequent anomalies are 20q-, 13q-, þ 8, þ 9, 12p-, and abnormalities of chromosomes 1 and 7. In our current LOH study, we were unable to detect allelic loss at 20q and 13q. However, when we used markers that map to the commonly deleted regions 20q11.2-13.1 and 13q14 as defined in the previous study, they were not informative in most patients. Nevertheless, using LOH analysis, we have expanded the findings of routine cytogenetics by identifying previously uncharacterized chromosomal deletions in patients with MMM.
In this study, we implicate the short arm of chromosome 3 as a locus for putative tumor suppressor genes whose inactivation is involved in the development of MMM. We observe allelic loss at 3p in 24% of patients with MMM and delineate a commonly deleted region approximately 4 Â 10 6 bp at 3p24. Deletions on 3p are among the most common losses in many types of cancer (Daly et al., 1993; Sekido et al., 1998; Wistuba et al., 2000; Huebner, 2001) ; therefore, the identification of tumor suppressors in this region has been ardently pursued. The growing list includes the VHL gene at 3p25.3 (Latif et al., 1993; Tyers and Rottapel, 1999) , RASSF1A at 3p21.3 (Dammann et al., 2000; Burbee et al., 2001 ), FHIT at 3p14.2 (Lisitsyn et al., 1995; Ohta et al., 1996) , DUTT1/ROBO1 at 3p12 (Xian et al., 2001) , and the recent addition RARb at 3p24. Since the LOH region we observe in MMM is located at 3p24, we hypothesized that inactivation of RARb is involved in the pathogenesis of myelofibrosis. It is possible that other genes located in this commonly deleted region are involved in the disease process, finer mapping of this area will be required to pinpoint definitively the implicated gene. However, we have focused on RARb because of its tumor suppressor function in other systems.
RARb is a member of the nuclear receptor superfamily of transcription factors that mediate the effects of retinoids by stimulating transcription from promoters containing retinoic acid-responsive elements (RAREs). Figure 4 Quantitative RT-PCR analysis of RARb expression in patients with MMM compared to normal. Gene expression was measured by real-time PCR using RNA from CD34 þ cells purified from patients with MMM (triangles) or normal individuals (squares). Each sample was analysed in triplicate, and 18S mRNA was used as an internal control. The median expression level for each group is indicated by the bar Figure 5 Expression of RARb during myeloid differentiation of CD34 þ cells. Total RNA was extracted from CD34 þ cells before and after culture with interleukin-3 and granuloctye-macrophage colony-stimulating factor. Cells were harvested on the days indicated, and RARb expression was measured in triplicate for each time point by real-time PCR. 18S was used as an internal control. Expression of CD34 and CD11b mRNA was measured by RT-PCR to confirm differentiation (inset) Figure 6 Methylation of the retinoic acid receptor-b P2 promoter in CD34 þ cells from patients with MMM and normal individuals. Genomic DNA was treated with bisulfite and amplified by PCR (as described in Materials and methods) using primers specific for unmethylated or methylated DNA. The resulting products were analysed by gel electrophoresis. A visible product in the RAR-M gel indicates that the RARb gene is methylated; a visible product in RAR-U indicates that the gene is unmethylated. C lane, positive control for methylation using universally methylated genomic DNA (Zhu et al., 2001; Shimizu and Takeda, 2000) . We find high levels of RARb2 in normal CD34 þ cells; however, it rapidly decreases by the promyelocytic stage. This result suggests a role for RARb2 in myeloid precursors. Our finding that RARb2 expression is lost in progenitor cells in 100% of patient samples provides the first evidence that this tumor suppressor may be involved in MMM. Since CD34 þ cells represent a heterogeneous population, the loss of RARb2 expression in MMM patients possibly correlates with the stage of differentiation of the cells. However, we would expect such heterogeneity to exist in CD34 þ cells from both MMM patients and normal individuals. Our interpretation that loss of RARb2 expression in MMM is relevant in the disease process is further supported by physical evidence, that is allelic loss and promoter methylation.
The importance of the RARb2 isoform in growth control has been demonstrated in many other systems. RARb2 has been shown to confer slower growth rates in epidermoid lung cancer cell lines and reduced tumorigenesis in nude mice (Houle et al., 1993) . Furthermore, overexpression of RARb2 in mammary cancer cell lines diminishes their growth rate and anchorage independence (Li et al., 1995; Si et al., 1996) . Although RARa is the first effector of RARb promoter 2, exogenous expression of RARb2 results in growth arrest even in breast cancer cell lines with scanty amounts of RARa (Liu et al., 1996) . How RARb2 exerts its anticancer effects is largely unknown, although RA-induced apoptosis and RA-independent antiactivator protein-1 activity have been implicated (Liu et al., 1996; Lin et al., 2000) . Using cDNA analysis in lung cancer cells, Toulouse et al. (2000b) showed that RARb2 regulates two genes essential for eliciting an effective cytotoxic immune response, major histocompatibility complex class I and intercellular adhesion molecule 1. Dysregulation of such genes might allow tumor cells to evade immune system detection. Whether or not RARb2 functions similarly in MMM is completely unknown as no correlation between RARb2 and regulation of hematopoietic proliferation has been established.
Our studies do, however, identify mechanisms that may be responsible for loss of RARb2 expression in MMM; they include both genetic and epigenetic changes. The results of our LOH analysis suggest that deletions on 3p contribute modestly to loss of RARb2 expression in MMM. The lack of correlation between allelic loss at 3p24 (21%) and loss of RARb2 expression (100%) indicates that additional mechanisms are involved in silencing of RARb2 in this disease. Methylation of cytosine residues in CpG dinucleotides of gene promoters is a mechanism commonly used by tumors to suppress transcription of genes that regulate growth. Tumor suppressor genes inactivated by hypermethylation include retinoblastoma-1 (Ohtani-Fujita et al., 1997), VHL in renal cancer (Prowse et al., 1997) , CDKN2B in hematologic malignancies (Batova et al., 1997) , and MLH1 and APC in colorectal cancer (Hiltunen et al., 1997; Herman et al., 1998; Veigl et al., 1998) . Our results indicate that hypermethylation of RARb2 occurs in 89% of patient samples, and, therefore, may be the predominant mechanism of silencing of RARb2 in MMM. Previous studies have shown that methylation of RARb P2 may be the most common mechanism of silencing RARb expression in small-cell lung cancer as well as non-small-cell lung cancer Zochbauer-Muller et al., 2001) . Furthermore, studies by Kuroki et al. (2003) suggest that hypermethylation of RARb may play an important role in the early stages of esophageal squamous cell carcinogenesis. Our observation that loss of RARb expression in MMM is likely due to methylation of the P2 promoter suggests that demethylating agents may be a potential approach to therapy in this disease. Additionally, combination chemotherapies including retinoid-based regimens along with chemical demethylation may be effective as 9-cis-retinoic acid treatment has been shown to restore expression of RARb expression in the bronchial epithelium and halt the progression of carcinogenesis (Kurie et al., 2003) . The mechanism by which DNA methyltransferases are recruited to RARb P2 and silence its expression in MMM is an area for future study.
Materials and methods

Clinical samples and DNA extraction
After approval by the institutional review board, 30 ml of peripheral blood was collected from patients with MMM, diagnosed according to conventional criteria. Hypaque density gradient centrifugation was used to separate out the granulocyte and mononuclear cell layers (Sigma Diagnostics, St Louis, MO, USA) from the samples. Each mononuclear cell layer was then further cell fractionated by MACS (Miltenyi Biotech, Auburn, CA, USA) using antibodies that are specific to myeloid precursors (CD34 þ ) as well as T (CD3 þ ) lymphocytes. The particular procedure was performed according to the manufacturer's recommendation. Sample purity in regards to CD34 cells and T-cell preparations was confirmed by flow cytometry. For methylation-specific PCR, 18 of the patient samples described above were used and compared with nine normal individuals. For the latter, bone marrow mononuclear cells were separated by density gradient centrifugation through Ficoll-Hypaque (Biochrom, Berlin, Germany). CD34 þ cells were purified as described previously (Hofmann et al., 2002) and purity was evaluated by flow cytometry. Genomic DNA was extracted using TRIzol (Invitrogen Corporation, Carlsbad, CA, USA).
LOH analysis
The LOH analysis was performed by PCR amplification of microsatellite sequences as described previously (Xie et al., 2000) . The primers were obtained from Research Genetics (Huntsville, AL, USA) and are listed in Table 1 . An additional 23 markers (listed in Figure 3) were selected for detailing mapping of chromosome 3p according to the International RH Mapping Consortium GeneMap'99. LOH was scored in informative cases if a significant reduction (450%) in the signal of the allele from the CD34 þ sample was observed in comparison with the corresponding allele from the CD3 þ sample of the same individual. In all samples showing LOH, PCR amplification and analysis were repeated to assure accuracy of results.
Methylation-specific PCR
The methylation status of RARb P2 was determined by methylation-specific PCR using bisulfite-modified DNA as described previously (Herman et al., 1996) . Genomic DNA was modified using the CpGenome DNA Modification Kit (Serologicals Corporation, Clarkston, GA, USA), and then PCR was performed with primers that were specific for either methylated or unmethylated RARb sequences. Primers used to amplify the methylated RARb gene were 5 0 -TCGAGAACGC-GAGCGATTCG-3 0 (forward) and 5 0 -GACCAATCCAACC-GAAACGA-3 0 (reverse). Primers used to amplify the unmethylated RARb gene were 5 0 -TTGAGAATGTGAGT-GATTTGA-3 0 (forward) and 5 0 -AACCAATCCAAC-CAAAACAA-3 0 (reverse). PCR amplification was performed under the following conditions: an initial denaturation at 941C for 5 min, 39 amplification cycles (30 s at 941C; 45 s at 581C (methylated) or 531C (unmethylated); and 45 s at 721C), followed by a final 5 min extension at 721C. PCR products were analysed on 2% agarose gels containing ethidium bromide.
Real-time PCR
Quantification of RNA in CD34 þ cells by real-time PCR was performed as described previously (Hofmann et al., 2001) . The following primers (Invitrogen Corporation) and probes (Applied Biosystems, Foster City, CA, USA) were used: RARb forwardprimer5 0 -AGAACCATTGCTGGAAGCAC-3 0 ;RARb reverse primer 5 0 -TGCACCTTTAGCACTGATGC-3 0 ; RARb oligoprobe 5 0 -FAM-AAAGACGACCCAGCAAGCCTCA-CAT-TAMRA-3 0 . Amplification reactions contained 100 ng of cDNA and 12.5 ml of the Universal Taqman 2X mastermix (Applied Biosystems). Concentrations of primer and TaqMan probes were 300 and 100 nM, respectively, in a final volume of 25 ml. All reactions were performed in triplicate using the iCycler iQt system (BioRad, Hercules, CA, USA) under the following conditions: 2 min at 501C, 10 min at 951C, followed by 45 cycles of 951C for 15 s and 601C for 1 min. 18S was used as an internal control.
Induction of myeloid differentiation
The CD34 þ cell population was purified and differentiated as described previously (Morosetti et al., 1997) except that cells were harvested on days 0, 2, 5, 7, 9, and 12 for RNA extraction.
